Material Fact – Grupo Biotoscana Announces Change in Management
GRUPO BIOTOSCANA ANNOUNCES CHANGE IN MANAGEMENT
BIOTOSCANA INVESTMENTS S.A. (“Company” or “GBT”) (B3: GBIO33), a leading biopharmaceutical company in Latin America, announces to its shareholders and the market in general that Mr. Claudio Coracini was appointed as the new Chief Executive Officer (interim) of Grupo Biotoscana. Mr. Federico Wintour is leaving the company. Change will be effective immediately.
The Board of Director thanks Mr. Wintour for his contributions to the Company over the last year and congratulate Mr. Coracini on his new attributions. He was the key driver of the transactional culture to integrate United Medical into GBT and will certainly help GBT move on to this next phase. Claudio will be the interim CEO on this transition period and will accumulate the function of Country Manager of Brazil.
Claudio has over forty years of experience in the pharmaceutical market, and, most importantly, he knows GBT and has been part of the team for the last 5 years. He was responsible for the Brazilian operations, leading the commercial structure, regulatory affairs, medical and compliance. During his management, United Medical was able to maximize the performance of the main products and launch 4 new innovative products in the country. Prior to joining GBT, Coracini worked at several pharmaceutical companies, such as Eli Lilly, Pfizer, Novo Nordisk and Shire.
He holds a degree in Social Communication from Escola Superior de Propaganda e Marketing (ESPM), and a master’s degree in Marketing from ESPM.
Please see the Press Release published today for more information.
Montevideo, October 21st, 2019
BIOTOSCANA INVESTMENTS S.A.
Legal Representative in Brazil
Updated on 10/21/2019 at 09:54 pm